Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II oral gimatecan in recurrent advanced epithelial ovarian, fallopian or peritoneal cancer
2005-000595-40Phase 2Completed
- Sponsor
- Sigma-Tau
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gimatecan in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Sigma-Tau. Primary endpoint: Objective response rate (RECIST or CA-125). Started May 2005; status: completed.
02
Drugs
gimatecan
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2005-000595-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000595-40.